Platinum (IV) drugs with cannabidiol inducing mitochondrial dysfunction and synergistically enhancing anti-tumor effects.

Chemotherapy resistance is an insurmountable problem in clinical anticancer therapy. Although Oxaliplatin is an effective chemotherapeutic agent for the treatment of colorectal cancer (CRC), it still suffers from serious toxicities as well as drug resistance. In this work, three Oxaliplatin tetravalent platinum prodrugs(O1-O3) and three novel mixed ammine/amine analogs(C1-C3) were constructed, introducing cannabidiol with anti-tumor activity in their axial position. All Pt(IV) prodrugs exhibited potent antitumor effects in a variety of tumor cell lines, especially in HCT-116 cells, where complex O3 showed strong inhibitory effects with the half maximal inhibitory concentrations (IC50) value of 6.02 ± 0.69 µM and about 2.6 times higher than that of Oxaliplatin. Further studies revealed that complex O3 decreased cellular mitochondrial membrane potential in a concentration-dependent manner and enhanced reactive oxygen species (ROS) accumulation by decreasing the expression of catalase, superoxide dismutase 2 (SOD2) and superoxide dismutase 3 (SOD3). Complex O3 induces mitochondrial dysfunction and upregulates the pro-apoptotic protein Noxa, ultimately leading to severe DNA damage. The upregulation of Phosphorylated histone protein H2AX (γ-H2AX) expression is clear evidence. In addition, O3 inhibits the expression of RAD51 protein and prevents DNA damage repair, thus overcoming drug resistance. This strategy of combining bioactive molecules cannabidiol with platinum drugs to improve therapeutic efficacy and overcome drug resistance has been proven to be very effective and deserves further investigation.

Turn-on Near-Infrared Phosphorescent Recognition of Anion Based on Self-Assembly of Cyclometalated Platinum Complexes That Induce Oncosis and Monitor Living Cells.

The design of bio-responsive functional molecular materials that can undergo self-assembly to form nanostructures within cells in response to cellular endogenous stimuli and the clarification of their prospective reaction mechanisms are of paramount significance. This work aims to elucidate the spatiotemporal generation of subcellular nanostructures and their influence on cellular functionality. Three sets of cyclometalated platinum complexes have been designed and synthesized as near-infrared phosphorescent turn-on probes for specific anions based on dynamic self-assembly in aqueous solution. The augmentation of the quantity of aromatic rings in the NN bidentate ligand of the complex modifies both the intensity of the intermolecular Pt-Pt interaction and the capacity to generate self-assembled nanowires with near-infrared emission. Besides, we explored the impact of the CN ligand's substituent effect on anion recognition, which revealed that complexes with electron-absorbing F atom substitution exhibit superior selectivity for Br-. These complexes display vivid green turn-on luminescence upon interaction with cellular biomolecules, enabling dynamic monitoring of their subcellular distribution and their interaction on diverse conditions. Furthermore, our complexes were observed to induce oncosis in cancer cells, underscoring the potential of our work in facilitating in vitro diagnosis and developing effective theranostic agents for cancer therapy.

A Series of Planar Phosphorescent Cyclometalated Platinum(II) Complexes as New Anticancer Theranostic Agents That Induce Oncosis.

Herein, four planar cyclometalated platinum(II) complexes with a main ligand of enlarged aromatic rings have been assessed as effective anticancer theranostic agents for the first time. With an increased number of aromatic rings in the N∧N ligand, 1a-1d exhibit increased lipophilicity and cytotoxicity selectivity. The intensity of the Pt-Pt interaction of each complex can be indicated by an enhanced near-infrared (NIR) emission in phosphate-buffered saline (PBS), their binding activity with biomolecules of bovine serum albumin (BSA) is accompanied by a vivid turn-on green emission, and the intensity gradually decreased from 1a to 1d, which is consistent with the docking of two complexes with BSA. Both "turn-on" NIR and green emission of 1d can be mainly observed in nuclei of living cell within 24 h, while two phosphorescence traces of 1b were recorded in lysosomes by confocal imaging. Moreover, 1d shows the highest efficiency in inducing oncosis of Hela cells, and the relative process was investigated.

Supramolecular fluorescent probe based on acyclic cucurbituril for detection of cancer Labels in human urine.

Spermine (Spm) and spermidine (Spmd) are considered as potential biomarker for early diagnosis of human cancer. Herein, a novel acyclic cucurbituril derivative (UL-ACB) was firstly designed and synthesized, which fluoresces at 460 nm after excitation at 365 nm. UL-ACB is rich in oxygen atoms which are capable of forming coordinate bonds with copper (Cu2+) that cause quenching of UL-ACB fluorescence. Moreover, the addition of biological endogenous substances Spm and Spmd can turn on fluorescence of UL-ACB. Interestingly, the probe showed a remarkable detection efficiency for Spm and Spmd in human urine (the detection limits of Spm and Spmd were 0.156 µM and 0.762 µM, and the linear ranges are 0.156 âˆ¼ 43.06 µM and 0.762 âˆ¼ 29.10 µM), which completely covered the early diagnosis of urinary Spm (1 âˆ¼ 10 µM) and urine Spmd (1 âˆ¼ 20 µM) required concentration range in cancer patients. The probe for Spm and Spmd is simple, time-saving and selective, which may provide a new promising strategy for early cancer diagnosis.

Anion-selective "Turn-on" two color phosphorescent probes based on "Pd-Pd" interaction of a series of cyclometallated Palladium (II) complexes induced by a self-assembly in aqueous solution.

Herein, three pairs of cationic cyclometallated palladium (II) complexes with different types of C^N ligands, which is non-phosphorescent in aqueous solution, interestingly, they can be utilized as turn-on blue phosphorescent probes selectively for ClO-, HSO3- and CO32-, and turn-on green phosphorescent probe for HSO3- in aqueous solution. These different phosphorescent turn-on responses of Pd(II) complexes could be attributed to the degree of coordination and electrostatic interaction between them with specific anion. It suggests that the selectivity towards specific anion of these cyclometallated Pd(II) complexes can be further improved by rationally tuning the structure and enhancing aromaticity of C^N ligand. Our study reveals that these specific species of anions can effectively induce self-assembly of Pd(II) compounds with different C^N ligand based on PdPd interaction, the aggregation and morphology of palladium complex with anion in aqueous media was also investigated by various means of 1H NMR, UV/Vis, fluorescence spectra, and dynamic light scattering (DLS) analysis. Moreover, transmission electron microscopy (TEM) reveals that nanowires with increased length of diameters of Pd complexes can form in aqueous solution in presence of anions with different high concentration. Furthermore, the cellular uptake and location of Pd2a was also investigated by confocal imaging for the first time. DFT calculation of monomer and dimer of Pd2a was also performed, which is helpful to explain the turn on phosphorescent effect during self-assembly process.

NIR phosphorescent cyclometalated platinum (II) complexes with CAIX targeted and nuclear penetration as potent anticancer theragnostic agents.

Although cisplatin drugs have achieved great success in cancer therapy, they also easily cause drug resistance and other side effects. Non-classical platinum (II) complexes with targeted therapy characteristics have become one of the hotspots in the research of new anticancer drugs. In the present work, a series of carbonic anhydrase IX (CAIX)-targeted and inhibited cyclometalated platinum (II) complexes with near-infrared (NIR) phosphorescent emission have been developed, due to the calculation of Molecular docking and the result of CAIX inhibition assay in vitro, all complexes show a high binding affinity and effective inhibition on CAIX in vitro. Moreover, Pt2 shows a significant cellar uptake efficiency, and translocation of red emission in Pt2 from the cytoplasm to nuclear in Hela cell can be recorded by confocal within 24 h, while Pt2 can selectively target and locate in the lysosome of MDA-MB-231 cell, thus resulting in significantly enhanced therapeutic effect on multiple cancer cell lines compared with cisplatin, as well as the killing selectivity towards cancer cell of CAIX-inhibited cyclometalated platinum (II) complex are 6.0-14.6 times higher than that of cisplatin. Hence, our work presents the rational design of Pt (II)-CAIX conjugates as a promising strategy in the application of constructing a new platform for cancer theragnostic agents.

Phosphorescent platinum (II), iridium (III) and ruthenium (II) complexes with monodentate imidazole ligands respond to the reductive microenvironment of living cells.

Phosphrescent complexes of monodentate imidazole have been reported before, but their dissociation induced by cellular endogenous stimulus have never been explored. In our work, the dissociation of monodentate imidazole ligands from phosphorescent cyclometalated platinum (II) iridium (III) and polypyridyl ruthenium (II) complexes in GSH abundant reductive solution are firstly investigated. The release rate of ligand follows the order: Pt (II) > Ir (III) > > Ru (II) in vitro, while their corresponding bidentate complexes are barely affected. Moreover, the cellular dissociation of ligand can be monitored in time by Confocal imaging and flow cytometry. In brief, cellular penetration and nucleolus targeting ability of GSH active complexes are mainly interfered by the reductive microenvironment. Our work may help to reveal the dynamic process of coordination and release of monodentate ligands of complexes in cellular microenvironment.

Self-Assembly System Based on Cyclodextrin for Targeted Delivery of Cannabidiol.

Cannabidiol (CBD) is one specific kind of the cannabinoid in Cannabis sativa L with a wide range of pharmacological activities. However, the poor water solubility and specificity of CBD limits its application in pharmaceutical field. For solving these problems, in this work, we successfully prepared a targeted carrier by grafting biotin (BIO) onto ethylenediamine-ß-Cyclodextrin (EN-CD) in a single step to generate a functionalized supramolecule, named BIO-CD. Subsequently, an amantadine-conjugated cannabinoids (AD-CBD) was prepared and self-assembled with the BIO-CD. A series of methods were used to characterize the inclusion behavior and physicochemical properties of AD-CBD and BIO-CD. The results showed that AD-CBD entered the cavity of BIO-CD and formed a 1:1 host-guest inclusion complex. MTT assay and confocal laser scanning microscopy (CLSM) revealed that the targeting effect and anticancer activity of AD-CBD/BIO-CD inclusion complex against three human cancer cell lines were higher than BIO-CD, AD-CBD and free CBD. Moreover, the inclusion complex could release drugs under weakly acidic conditions. These results demonstrated that AD-CBD/BIO-CD inclusion complex possess excellent targeted and anticancer activity, which is hopeful to be applied in clinic as a new therapeutic approach.

Codelivery of satraplatin and aminopyrrolic receptor with Pluronic F127-based polyaniline nanoparticles with NIR induced release for combined chemotherapy.

The acquired drug resistance of the platinum-based drug is a main obstacle in cancer therapy. Herein, an aminopyrrolic receptor 1 was synthesized to sensitize satraplatin for overcoming the drug resistance as well as improving tumor targeted ability. Thus, Pluronic F127-based polyaniline nanoparticles were designed to co-deliver satraplatin and aminopyrrolic receptor 1, which could control the drug release with the Near Infrared laser irradiation (808 nm) due to the polyaniline mediated photothermal conversion. Biological evaluation shows prepared nanoparticles (Pt-ARNPs) exhibited more effective cytotoxicity (IC50 = 2.7µM) against the tested cancer cell lines under laser irradiation, compared with free satraplatin or treatment without Near-infrared radiation. Moreover, Pt-ARNPs showed comparable cytotoxicity against A549 and A549/cis cells, implying that the combination of satraplatin and aminopyrrolic receptor 1 with nano carrier might be a promising strategy to reduce platinum resistance and improve therapeutic effect in cancer therapy.

Reversing the cytotoxicity of uric acid by supramolecular encapsulation with acyclic cucurbit[n]uril.

Supramolecular encapsulation, which removes harmful substances from organisms, has evolved into a new strategy. In this paper, three supramolecular complexes of acyclic cucurbit[n]urils (ACBs) with uric acid (UA) were prepared, and the inclusion behavior of ACBs and UA was studied by fluorescence spectroscopy, UV-vis spectroscopy and nuclear magnetic resonance. Furthermore, the effect of the complexes of UA with ACBs on the expression of inflammatory biomarkers in human hepatoma HepG2 cell lines was characterized through C-reactive protein (CRP) western blot. The results showed UA molecules can be recognized by three ACBs with different binding constants, and ACBs successfully blocked the inflammatory stimulation of UA on HepG2 cell lines and inhibited the expression of the major inflammatory factor CRP by the formation of complexes between UA and ACBs. This article proves that ACBs can efficiently reverse the cytotoxicity of UA, which provides a new method for treating hyperuricemia disease.

Iridium(III) Complex-Derived Polymeric Micelles with Low Dark Toxicity and Strong NIR Excitation for Phototherapy and Chemotherapy.

Iridium(III) complexes are potent candidates for photodynamic therapy. However, their clinical usage is impeded by their poor water solubility, high dark toxicity, and negligible absorption in near-infrared region (NIR region). Here, it is proposed to solve these challenges by developing an iridium(III) complexe-based polymeric micelle system. This system is self-assembled using an iridium(III) complex-containing amphiphilic block polymer. The upconversion nanoparticles are included in the polymeric micelles to permit NIR excitation. Compared with the nonformulated iridium(III) complexes, under NIR stimulation, this polymeric micelle system exhibits higher 1 O2 generation efficiency, negligible dark toxicity, excellent tumor-targeting ability, and synergistic phototherapy-chemotherapy effect both in vitro and in vivo.

Targeting drug delivery system for platinum(â £)-Based antitumor complexes.

Classical platinum(II) anticancer agents are widely-used chemotherapeutic drugs in the clinic against a range of cancers. However, severe systemic toxicity and drug resistance have become the main obstacles which limit their application and effectiveness. Because divalent cisplatin analogues are easily destroyed in vivo, their bioavailability is low and no selective to tumor tissues. The platinum(IV) prodrugs are attractive compounds for cancer treatment because they have great advantages, e.g., higher stability in biological media, aqueous solubility and no cross-resistance with cisplatin, which may become the next generation of platinum anticancer drugs. In addition, platinum(IV) drugs could be taken orally, which could be more acceptable to cancer patients, breaking the current situation that platinum(II) drugs can only be given by injection. The coupling of platinum(IV) complexes with tumor targeting groups avoids the disadvantages such as instability in blood, irreversible binding to plasma proteins, rapid renal clearance, and non-specific distribution in normal tissues. Because of the above advantages, the combination of platinum complexes and tumor targeting groups has become the hottest field in the research and development of new platinum drugs. These approaches can be roughly categorized into two groups: active and passive targeted strategies. This review concentrates on various targeting and delivery strategies for platinum(IV) complexes to improve the efficacy and reduce the side effects of platinum-based anticancer drugs. We have made a summary of the related articles on platinum(IV) targeted delivery in recent years. We believe the results of the studies described in this review will provide new ideas and strategies for the development of platinum drugs.

Inclusion complexes between chrysin and amino-appended ß-cyclodextrins (ACDs): Binding behavior, water solubility, in vitro antioxidant activity and cytotoxicity.

Solid inclusion complexes between chrysin and four amino-appended ß-cyclodextrins (ACDs) were prepared by suspension method and characterized in solid and solution states by kinds of analytical methods. The scanning electron microscopy (SEM) showed distinct micro-morphologies of them. Thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) analysis revealed their unique thermal properties, such as decomposition temperatures and endothermic points. Powder X-ray diffractometry (XRD) analysis disclosed their unique crystal patterns. Their nuclear magnetic resonance (NMR) analyses provided the variations of chemical shifts before and after the formation of inclusion complexes. Their binding stability constants (Ks) were 574, 842, 704, and 474 L·mol-1, respectively, as determined by spectral titration. A 1:1 inclusion mode with self-assembly of their amino side chains inside the ACD cavity was proposed based on Job plot and 2D-ROESY experiments. Water solubility of chrysin was promoted up to 4411.98 µg·mL-1 after formation of inclusion complexes with ACDs, better than that of ß-CD and its derivatives, i.e., HP- and SBE-ß-CD. In vitro antioxidant activity of chrysin was also improved after inclusion complexation by the DPPH scavenging assay. Furthermore, in vitro cytotoxicity of solid inclusion complexes towards three human cancer cell lines, A549, HT-29 and HCT116 were enhanced significantly.

Copper-Catalyzed Decarboxylative Disulfonylation of Alkynyl Carboxylic Acids with Sulfinic Acids.

A copper-catalyzed decarboxylative disulfonylation of alkynyl carboxylic acids with sulfinic acids in aqueous solution has been developed. The reaction provides a straightforward and practical access to (E)-1,2-disulfonylethenes, which are important building blocks in synthetic organic chemistry, and exhibits a good functional group tolerance and excellent stereoselectivity. A possible mechanism for the transformation is proposed.

Research progress in modern structure of platinum complexes.

Since the antitumor activity of cisplatin was discovered in 1967 by Rosenberg, platinum-based anticancer drugs have played an important role in chemotherapy in clinic. Nevertheless, platinum anticancer drugs also have caused severe side effects and cross drug resistance which limited their applications. Therefore, a significant amount of efforts have been devoted to developing new platinum-based anticancer agents with equal or higher antitumor activity but lower toxicity. Until now, a large number of platinum-based complexes have been prepared and extensively investigated in vitro and in vivo. Among them, some platinum-based complexes revealing excellent anticancer activity showed the potential to be developed as novel type of anticancer agents. In this account, we present such platinum-based anticancer complexes which owning various types of ligands, such as, amine carrier ligands, leaving groups, reactive molecule, steric hindrance groups, non-covalently binding platinum (II) complexes, Platinum(IV) complexes and polynuclear platinum complexes. Overall, platinum-based anticancer complexes reported recently years upon modern structure are emphasized.

Design, synthesis and biological evaluation of six dinuclear platinum(II) complexes.

Six dinuclear platinum(II) complexes with a chiral tetradentate ligand, (1R,1'R,2R,2'R)-N1,N1'-(1,4-phenylenebis(methylene))dicyclohexane-1,2-diamine, have been designed, synthesized and characterized. In vitro cytotoxicity evaluation of these metal complexes against human A549, HCT-116, MCF-7 and HepG-2 cell lines have been carried out. All compounds showed antitumor activity to HepG-2, HCT-116 and A549. Particularly, compounds A1 and A2 exhibited significant better activity than other four compounds and A2 even showed comparable cytotoxicity to cisplatin against HepG-2 cell line.

Inorganic Nano-Targeted Drugs Delivery System and Its Application of Platinum-Based Anticancer Drugs.

As one of the most important anticancer drugs, cisplatin and its analogues have been widely used in chemotherapy regimens of various tumors. However, a series of side effects and resistance/cross-resistance have been becoming the main obstacles which limit their application and effectiveness. Recent researches suggest that inorganic nano-materials which act as targeted drug delivery carriers of platinum-based anticancer drugs not only enhance the antitumor activity of platinum-based drugs, but also reduce the side effects and resistance. The nano-targeted drugs delivery system provides a new strategy in clinical application of platinum-based anticancer drugs. This review will focus on recent advances in inorganic nano-carriers for platinum-based targeted drugs delivery system.

Host-guest inclusion system of rhein with polyamine-modified ß-cyclodextrins: characterization and cytotoxicity.

We report the preparation of inclusion complexes between rhein and four polyamine-modified ß-cyclodextrins, namely amino-ß-cyclodextrins (NH2-ßCD), ethylenediamine-ß-cyclodextrins (EN-ßCD), diethylenetriamine-ß-cyclodextrins (DETA-ßCD) and triethylenetetramine-ß-cyclodextrins (TETA-ßCD) using suspension method. The solution and solid state forms of the inclusion complexes of rhein with polyamine-ß-cyclodextrins were characterized by multiple techniques. Additionally, saturated solution and MTT methods were implemented to assess the water solubilization and in vitro cytotoxicity of the inclusion complexes, respectively. The results suggested that rhein was encapsulated within the CD cavity to form a 1:1 host-guest inclusion complex. Notably, a significant enhancement of the water solubility and in vitro cytotoxicity of rhein was found in the form of inclusion complex with polyamine-ß-cyclodextrin.

Targeted Drug Delivery System for Platinum-based Anticancer Drugs.

Platinum-based (Pt-based) anticancer drugs have been recognised as one of the most effective drugs for clinical treatment of malignant tumors due to its unique mechanism of action and broad range of anticancer spectrum. But, there are still some limitations such as side effects, drug resistance/cross resistance, no-specific targeting, becoming obstacles to restrict its expanding of clinical application. Targeted drug delivery system (TDDS) is a promising strategy for the research of novel Pt-based anticancer drugs. A variety of TDDS have been explored to improve the antitumor activity of Pt-based drugs such as nanoparticle drug systems, polymer-drug systems, drugs-macrocyclic compounds systems, etc. The review concentrates on recent development of various targeted drug delivery techniques, which could provide more opportunities for the development of Pt-based drugs with better efficiency, lower toxicity and less resistance.

[Research progress of the drug delivery system of antitumor platinum drugs with macrocyclic compounds].

Platinum-based anticancer drugs have been becoming one of the most effective drugs for clinical treatment of malignant tumors for its unique mechanism of action and broad range of anticancer spectrum. But, there are still several problems such as side effects, drug resistance/cross resistance and no-specific targeting, becoming obstacles to restrict its expanding of clinical application. In recent years, supramolecular chemistry drug delivery systems have been gradually concerned for their favorable safety and low toxicity. Supramolecular macrocycles-platinum complexes increased the water solubility, stability and safety of traditional platinum drugs, and have become hot focus of developing novel platinum-based anticancer drugs because of its potential targeting of tumor tissues/organs. This article concentrates in the research progress of the new drug delivery system between platinum-based anticancer drugs with three generations of macrocycles: crown ether, cyclodextrin, cucurbituril and calixarene.